Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Podcasts|October 8, 2026

The BioPharm Brief: Rare Disease Trials, mRNA Innovation, and Funding

New clinical milestones, manufacturing investments, and regulatory incentives could help developers overcome barriers to delivering treatments for patients with rare diseases.

Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research, clinical progress, and drug development. Today’s update examines the path forward for a rare disease gene therapy, new funding for cell-based messenger RNA (mRNA) manufacturing, and how regulatory incentives can help finance future treatments for rare diseases.

Rocket Pharmaceuticals has outlined its remaining steps toward completing the pivotal phase 2 trial of RP-A501, an investigational gene therapy for Danon disease. Following a clinical hold that FDA lifted in 2025, the company is using a modified protocol and recalibrated dose. The trial will enroll 12 male patients, with success requiring at least 7 to meet 2 cardiac endpoints after 12 months. Rocket expects to complete dosing by mid-2027 and report topline results in mid-2028. The small trial and the program’s earlier serious safety events underscore the challenges of developing gene therapies for rare, potentially life-threatening diseases.

Beyond clinical progress, manufacturing innovation remains a key challenge for advanced therapies. Sensible Biotechnologies has raised $47 million to scale its cell-based mRNA manufacturing platform and develop clinical-grade production capabilities. Its approach uses engineered living cells to produce naturally modified mRNA, aiming to reduce unwanted immune activation and improve protein expression compared with conventional synthetic production. The funding will support platform scale-up, artificial intelligence-enabled design, and automated screening. However, the company has not yet reported clinical data, and its ability to deliver consistent, cost-effective production at scale remains to be demonstrated.

On the financing front, Ultragenyx has agreed to sell an FDA priority review voucher for $210 million. The company earned the voucher following approval of Genglycos, a gene therapy for glycogen storage disease type Ia. Ultragenyx plans to use the proceeds to support development of additional rare and ultra-rare disease treatments. The transaction remains subject to customary closing conditions, illustrating how regulatory incentives can generate capital for future research.

These developments underline the multiple factors shaping rare disease drug development, from demonstrating clinical benefit and scaling innovative manufacturing platforms to securing capital for future research.

Thanks for listening to The BioPharm Brief. For more analysis and expert insights, please visit www.BioPharmInternational.com.

Key takeaways

  • Rocket Pharmaceuticals targets mid-2028 results for its Danon disease gene therapy.
  • Sensible Biotechnologies raises $47 million to scale cell-based mRNA manufacturing.
  • Ultragenyx plans to reinvest a $210 million voucher sale in rare disease drug development.


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.